Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 72 citing articles:

Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review
Achille Aveta, Simone Cilio, Roberto Contieri, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10846-10846
Open Access | Times Cited: 55
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Fan Yang, Chloe Shay, Marin Abousaud, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 36
Urinary Micro-RNAs As Biomarkers of Urological Cancers: A Systematic Review
Achille Aveta, Simone Cilio, Roberto Contieri, et al.
(2023)
Open Access | Times Cited: 30
Application of Nanoparticles in Cancer Treatment: A Concise Review
Mariana Sell, Ana Rita Lopes, Maria Escudeiro, et al.
Nanomaterials (2023) Vol. 13, Iss. 21, pp. 2887-2887
Open Access | Times Cited: 28
Nanotherapeutics for prostate cancer treatment: A comprehensive review
Ruimin Hu, Lan Jin, Dinglin Zhang, et al.
Biomaterials (2024) Vol. 305, pp. 122469-122469
Closed Access | Times Cited: 9
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
Blaine Brower, Asia S. McCoy, Hiba Ahmad, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 9
A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers
Ehsan Zolfi, Farhood Khaleghi mehr, Nikoo Emtiazi, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
Yuxuan Song, Yun Peng, Caipeng Qin, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e006643-e006643
Open Access | Times Cited: 19
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
Luigi Napolitano, Celeste Manfredi, Luigi Cirillo, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 767-767
Open Access | Times Cited: 16
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
Alberto Gil-Jimenez, Nick van Dijk, Joris L. Vos, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy
Lihui Xuan, Chenjun Bai, Zhao Ju, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 75, pp. 1-11
Closed Access | Times Cited: 13
Advances in and prospects of immunotherapy for prostate cancer
Deng Liu, Luofu Wang, Yanli Guo
Cancer Letters (2024) Vol. 601, pp. 217155-217155
Open Access | Times Cited: 5
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)
Shanshan Yang, Suya Zhao, Yixiang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
Xuhui Tong, Rong Tang, Jin Xu, et al.
Heliyon (2025) Vol. 11, Iss. 1, pp. e41597-e41597
Open Access
The Safety and Efficacy of Immune Checkpoint Blockade in Children, Adolescents, and Young Adults: A Systematic Review and Meta-Analysis
Pedro Cotta Abrahão Reis, João Evangelista Ponte Conrado, Mariana Macambira Noronha, et al.
EJC Paediatric Oncology (2025), pp. 100215-100215
Open Access
Photochemical bomb: Precision nuclear targeting to activate cGAS-STING pathway for enhanced bladder cancer immunotherapy
Dexiang Feng, Xiaoying Kang, He Wang, et al.
Biomaterials (2025), pp. 123126-123126
Closed Access
Incidence and management of hepatic immune‑related adverse events in advanced urologic cancers treated with immune checkpoint inhibitors: A multicenter retrospective study
Young Joo Park, Chan Ho Lee, Won Ik Seo, et al.
Oncology Letters (2025) Vol. 29, Iss. 4, pp. 1-11
Open Access
Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study
Tiphaine Boucheron, Laurent Chiche, Guillaume Pénaranda, et al.
Therapeutics and Clinical Risk Management (2025) Vol. Volume 21, pp. 273-282
Open Access
Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system
Bahadır Köylü, Buğra Han Esen, Şevval Nur Bektaş, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Research Progress on Adverse Events of Immune Checkpoint Inhibitors
洪益 肖
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1493-1500
Closed Access
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Pooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e011273-e011273
Open Access
Single-cell and bulk RNA-sequence identify an immune-derived lncRNA-mRNA signature for predicting clinical outcomes and immunotherapeutic response of prostate cancer
Ren Liu, Hiocheng Un, Renxuan Lin, et al.
International Journal of Biological Macromolecules (2025), pp. 143014-143014
Open Access
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
Nadia Guezour, Ghassen Soussi, Solenn Brosseau, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3878-3878
Open Access | Times Cited: 17
NCKAP1 is a Prognostic Biomarker for Inhibition of Cell Growth in Clear Cell Renal Cell Carcinoma
Jiasheng Chen, Jianzhang Ge, Wancong Zhang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 16
Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
Tian Zhang, Yi Wang, Chunhui Shi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top